Guerbet
GBT.PAGBT.PA · Stock Price
Historical price data
Overview
Guerbet S.A. is a global specialist in contrast media and solutions for medical imaging, with a mission encapsulated in its tagline 'Visibly Different.' The company has achieved a leading position through a century of innovation, most recently marked by the European approval of its half-dose MRI agent, Elucirem™, for use in children from birth. Its strategy focuses on advancing its core platform of gadolinium and iodinated agents, while navigating a challenging financial period to return to sustainable growth and profitability.
Technology Platform
Specialized chemistry and formulation platform for contrast media agents used in MRI (gadolinium-based), CT (iodinated), ultrasound (microbubbles), and interventional radiology.
Pipeline
50| Drug | Indication | Stage | Watch |
|---|---|---|---|
| DOTAREM | Magnetic Resonance Imaging | Approved | |
| Dotarem®-enhanced MRI | Renal Insufficiency | Approved | |
| Xenetix + Visipaque | Diagnostic Imaging | Approved | |
| Dotarem + Gadovist | Peripheral Arterial Disease | Approved | |
| Ioversol 320 mgI/mL + Iodixanol 320 mgI/mL | Renal Impairment | Approved |
Opportunities
Risk Factors
Competitive Landscape
Guerbet competes in a consolidated global market against giants like Bayer and GE HealthCare, as well as specialists like Bracco Imaging. Its differentiation relies on its half-dose MRI agent and pediatric indication, but it battles the vast commercial scale and resources of its larger competitors daily.